3-o-Tolyloxy-propan-1,2-diol-2-monocarbamat | 2049-31-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-o-Tolyloxy-propan-1,2-diol-2-monocarbamat
• 英文别名: Mephenesin-β-carbamat；carbamic acid-(β-hydroxy-β'-o-tolyloxy-isopropyl ester)；Carbamidsaeure-(β-hydroxy-β'-o-tolyloxy-isopropylester)；mephenesin carbamate；[1-Hydroxy-3-(2-methylphenoxy)propan-2-yl] carbamate
• CAS: 2049-31-2
• 化学式: C₁₁H₁₅NO₄
• 分子量: 225.244
• InChiKey: PZEYAHBHSHMJBF-UHFFFAOYSA-N

物化性质

• 熔点：
  115.0-115.6 °C
• 沸点：
  438.7±40.0 °C(predicted)
• 密度：
  1.222±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  81.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  邻甲苯缩水甘油醚 在 吡啶 、 盐酸 作用下， 以 乙醇 为溶剂， 生成 3-o-Tolyloxy-propan-1,2-diol-2-monocarbamat
  参考文献：
  名称：

  Some Derivatives and Analogues of Mephenesin

  摘要：

  报道了一些与美芬甙形式上相关的杂类的制备。

  DOI：

  10.1111/j.2042-7158.1960.tb12628.x

文献信息

• Analgesic and glucosamine compositions
  申请人：Temple University of the Commonwealth of Higher Education

  公开号：US20020058642A1

  公开（公告）日：2002-05-16

  This invention relates to a composition comprising a glucosamine material and an analgesic compound such as a nonsteroidal anti-inflammatory drug (NSAID) and/or an opioid analgesic and its use for treatment of pain in pharmaceutical or veterinary applications. When the components of the compositions are administered within certain ratios, the analgesic efficacy of the composition is super-additive (synergistic) relative to the analgesic efficacy of the analgesic compound alone.

  本发明涉及一种包含葡萄糖胺物质和镇痛化合物（如非甾体抗炎药（NSAID）和/或阿片类镇痛剂）的组合物及其在药物或兽医应用中用于治疗疼痛的用途。当组合物的成分在一定比例内给予时，相对于单独使用镇痛化合物，组合物的镇痛效果是超加性（协同作用的）。
• Pharmaceutical composition of matter
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0031603A1

  公开（公告）日：1981-07-08

  A composition for improved absorption of drugs which are poorly water-soluble and poorly absorbed. Particularly this invention relates to a composition of matter in pharmaceutical dosage form comprising 4-(monoalkylamino)benzoic acid and derivatives and non-ionic surfactants, providing enhanced blood levels of 4-(monoalkylamino)benzoic acid and derivatives for the treatment of atherosclerosis hypolipidemia. A method of increasing drug absorption (particularly 4-(monoalkylamino)benzoic acid and derivatives) by administration of such drug in concert with greater than about 10% surfactant is described.

  一种改善水溶性差、吸收率低的药物吸收的组合物。特别是本发明涉及一种药物剂型的物质组合物，包括 4-(单烷基氨基)苯甲酸及衍生物和非离子表面活性剂，可提高 4-(单烷基氨基)苯甲酸及衍生物的血药浓度，用于治疗动脉粥样硬化低血脂症。描述了一种通过与大于约 10%的表面活性剂配合使用来增加药物吸收（特别是 4-（单烷基氨基）苯甲酸及衍生物）的方法。
• Substained release polymer blend matrix for pharmaceutical application
  申请人：HERCULES INCORPORATED

  公开号：EP0875245A2

  公开（公告）日：1998-11-04

  A pharmaceutical composition has a blend of at least first and second components and a medicament in a sufficient amount to be therapeutic where the first component is selected from hydroxypropylcellulose (HPC), ethylcellulose (EC), or derivatives of HPC, EC and hydroxyethylcellulose (HEC) and the second component is at least one polymer. When HPC is the first component, hydroxypropylmethyl-cellulose (HMC), HEC or carboxymethylcellulose will not be the second component and when EC is the first component, HPMC will not be the second component. The medicament can be a variety of drugs or nutritional supplements. The pharmaceutical composition releases the medicament for a prolonged or sustained period of time and can be formulated into many dosage forms.

  一种药物组合物至少含有第一和第二成分以及足够治疗量的药物，其中第一成分选自羟丙基纤维素（HPC）、乙基纤维素（EC）或 HPC、EC 和羟乙基纤维素（HEC）的衍生物，第二成分是至少一种聚合物。当 HPC 为第一成分时，羟丙基甲基纤维素（HMC）、HEC 或羧甲基纤维素不会成为第二成分；当 EC 为第一成分时，HPMC 不会成为第二成分。药品可以是各种药物或营养补充剂。药物组合物可以长时间或持续释放药物，并可配制成多种剂型。
• Preparation of submicron sized particles with polymorph control
  申请人：——

  公开号：US20030096013A1

  公开（公告）日：2003-05-22

  The present invention provides a method of preparing particles with polymorph and size control of a pharmaceutical compound, the method including the steps of: (1) providing a pharmaceutical compound in a first phase; (2) seeding the compound; (3) causing a phase change in the pharmaceutical compound to a second phase of a desired polymorphic form; and (4) wherein the mean particle size of the particles is less than 7 &mgr;m.

  本发明提供了一种制备具有多晶型和尺寸控制的药物化合物颗粒的方法，该方法包括以下步骤：(1)提供第一相中的药物化合物；(2)播种该化合物；(3)使药物化合物发生相变，变成所需多晶型的第二相；(4)其中颗粒的平均粒度小于7&mgr;m。
• ANALGESIC, ANTI-INFLAMMATORY AND SKELETAL MUSCLE RELAXANT COMPOSITIONS
  申请人：SUNSHINE, Abraham

  公开号：EP0205492A1

  公开（公告）日：1986-12-30